Related Experiment Video
Updated: Aug 4, 2025

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
New late-emphasis and combination tests based on infimum and supremum logrank statistics with application in oncology
Jean Marie Boher1,2, Thomas Filleron3, Pierre Bunouf4
1Biostatistics and Methodology Unit, Institut Paoli-Calmettes, Marseille, France.
Abstract:
Immunotherapy cancer clinical trials routinely feature an initial period during which the treatment is given without evident therapeutic benefit, which may be followed by a period during which an effective therapy reduces the hazard for event occurrence. The nature of this treatment effect is incompatible with the proportional hazards assumption, which has prompted much work on the development of alternative effect measures of frameworks for testing. We consider tests based on individual and combination of early- and late-emphasis infimum and supremum logrank statistics, describe how they can be implemented, and evaluate their performance in simulation studies. Through this work and illustrative applications we conclude that this class of test statistics offers a new and powerful framework for assessing treatment effects in cancer clinical trials involving immunotherapies.
More Related Videos
Related Concept Videos
The Mantel-Cox Log-Rank Test
Comparing the Survival Analysis of Two or More Groups
Cancer Survival Analysis
Kaplan-Meier Approach
Survival Curves
The Kaplan-Meier estimator is the most common method for constructing survival curves. This...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...

